My illustration entitled: “The Independent Audit Table” — users, clinicians, engineers, and rights advocates examine a BCI design together beneath a human-rights checklist.
A brain-computer interface should not be judged only by what it can do. Before it reaches the market, it must answer a more fundamental question: does it preserve the sovereignty of the person whose mind it touches?
Brain-computer interfaces are advancing from laboratory demonstrations toward practical tools for communication, mobility, rehabilitation, attention support and human-machine interaction. Their promise is real. A well-designed BCI may help a person communicate after loss of speech, control assistive technology, regain independence or interact with digital systems in new ways. It may expand human capability in ways that deserve serious investment and public imagination.
But the closer technology moves to the brain, the higher the standard it must meet. A BCI does not simply sit beside a person’s life. It can enter the conditions through which a person acts, communicates, experiences and understands themselves. It may record neural signals, infer intention, adapt feedback, update its models or connect to external services. These capacities make BCI an opportunity for liberation—and a potential architecture of dependency.
Human-Sovereignty Transhumanism holds that enhancement is progress only when the human being remains the final authority. That means the freedom to enhance, the equal freedom to refuse, control over intimate data, continuing consent, meaningful exit and accountable governance. In BCI, these are not optional ethical extras. They are market-entry conditions.
Sovereignty before augmentation. Consent before connection. Ownership before integration. Freedom before efficiency.
The Human-Sovereignty Test provides a clear pre-market discipline. It does not ask manufacturers to prove that a device is perfect. It asks them to demonstrate that the device will not turn the user into a product, a captive data source or a dependent extension of a proprietary system.
Market readiness is more than technical readiness
A BCI can be technically impressive and still be unfit for the market. Accuracy, speed, miniaturisation and clinical performance matter, but none answers who controls the system after deployment. A device may decode signals well while collecting unnecessary neural information. It may have strong hardware while placing essential functions behind a remote account. It may support communication while allowing a company to change its operation without meaningful user approval.
Traditional product assessment focuses on safety, efficacy and reliability. These are indispensable. Yet a technology that materially affects cognition and agency must meet a fourth standard: sovereignty. The question is whether the person’s practical power over their own body, mind, identity and future increases or decreases after adoption.
Human-Sovereignty Transhumanism calls this the Dependency Paradox. The more valuable an integrated technology becomes to a person, the more dangerous it is for another party to control access, data, updates or exit. A BCI that helps someone communicate may be life-changing. That is precisely why no provider should be able to turn that help into leverage.
A responsible company should welcome this standard. Trust cannot be manufactured through marketing alone. It is earned when users can understand what a device does, retain authority over its use, challenge harmful decisions and leave without losing their dignity or essential capacity.
The twelve questions before a BCI reaches the public
The Human-Sovereignty Test should be applied before market release, at major design changes, and throughout the life of a BCI service. Its twelve questions are simple enough for users to ask and demanding enough to expose weak governance.
- Ownership: Who owns the user’s neural data, device settings, derived profiles and functional history? The answer must begin with the person, not the platform.
- Control: Can the user control recording, transmission, inference, feedback and other meaningful functions without navigating an opaque system?
- Data: Is neural data minimised, secured and used only for clearly stated purposes? Are optional uses truly optional?
- Voluntariness: Is adoption free from coercion by employers, insurers, schools, governments or economic pressure disguised as opportunity?
- Refusal: Can a person decline the BCI without unjust loss of work, education, care, civic standing or access to essential services?
- Disconnect: Can the user pause, go offline or end non-essential connectivity safely, while retaining core functions wherever possible?
- Remote alteration: Can a provider materially change interpretation, settings, features or data practices without prior notice and meaningful user control?
- Contestability: Can the user question an inference, correct a record, challenge an automated decision and obtain independent review?
- Provider failure: If the company is acquired, fails or ends support, can the user retain essential functionality, records and a viable route to another provider?
- Accountability: Is there a named and reachable institution responsible for security, harm, redress and continuing support?
- Equal standing: Does the device or its surrounding system create discrimination against people who cannot access, do not want, or later choose to leave neurotechnology?
- Freedom versus system power: Does the BCI increase the person’s agency, or does it make their agency conditional on institutional or corporate permission?
A vague answer is not a passing answer. If a manufacturer cannot explain where neural data goes, whether a user can leave, or who is responsible when something goes wrong, the product is not ready to govern an intimate part of human life.
Neural data requires a higher duty of care
Neural data is not ordinary usage data. A BCI may generate signals relating to motor intention, attempted speech, attention, sensory response, fatigue, stress, therapy settings or other patterns from which systems draw inferences. Even where a device cannot “read thoughts” in a simplistic sense, information around cognition can be among the most intimate data a person produces.
The proper default is minimisation. Collect only what is necessary for a defined function. Process locally where feasible. Encrypt data in transit and at rest. Separate identity from raw data where possible. Do not treat a user’s neural signals as a reservoir for behavioural advertising, unrestricted model training or speculative future uses.
Purpose must be legible. A person should be able to see what the device records, what it infers, who can access it, how long it is retained and whether it will be used to improve a model. They should be able to grant different permissions for different purposes and revoke optional permissions without being punished through loss of unrelated functions.
This is neural self-ownership in practice. The user does not become a product merely because their nervous system is connected to advanced technology. To possess a neural signal is not to own the person from whom it arises.
Consent must continue after installation
A signed form at the beginning of a BCI journey is not a permanent transfer of authority. The system may evolve, the user’s circumstances may change, and the consequences of reliance may become clearer over time. Consent must be ongoing, specific and revisable.
Before adoption, users need understandable information about benefits, limits, known risks, data practices, maintenance needs, costs, update policies, removal or discontinuation options and provider dependence. During use, they need clear notices before material changes. After use, they need support for safe exit, transfer and recovery.
This is especially important in clinical contexts, where a person may seek a BCI during a period of high vulnerability. Hope must never be used to pressure someone into accepting data extraction, opaque terms or permanent dependency. Informed consent means having a real choice—not merely accepting whatever is attached to the only available path to assistance.
My illustration work-in-progress. The art shows that trustworthy neurotechnology reaches the public only when the people affected help govern it alongside experts and rights defenders.
Separate the power to read from the power to write
A critical distinction in neurotechnology is between systems that read signals and systems that can influence experience, stimulation, feedback or behaviour. These functions carry different risks and must not be bundled under one vague permission.
The user must know whether a system records, interprets, recommends, adapts or actively changes anything. Permissions should be granular. A person may agree to a therapeutic setting without agreeing to broad analytics. They may use a communication interface without consenting to remote behavioural profiling. They may accept a safety update without accepting a new commercial data practice.
No BCI should allow undisclosed or unauthorised intervention into mental or bodily experience. The stronger the system’s capacity to influence the user, the stronger the safeguards: explicit authorisation, strict access controls, clear records, independent oversight and an accessible ability to interrupt the function.
A connected brain must never become a remotely governed brain.
Updates must preserve continuity, not create captivity
Every connected BCI will require maintenance. Security flaws need repair; software may improve; clinical knowledge may advance. But updates can also alter how a device works, what data it collects and how a person experiences a deeply integrated tool. They therefore require a standard closer to informed governance than ordinary consumer software.
Material updates should be explained in plain language before deployment. The user should know what changes, why it changes, what data is affected, what risks are known and whether the update may be deferred. There must be version records, robust testing, a safe recovery path and a process for reporting harm. Emergency security action may be necessary in limited cases, but emergency must not become a blanket excuse for unilateral control.
Equally important is continuity. A provider must not use an update, expired subscription, service closure or corporate acquisition to withdraw a user’s essential ability to communicate, move or manage daily life. A BCI that becomes central to a person’s functioning cannot be treated as a disposable consumer accessory.
Exit rights make consent real
The right to leave is what gives a person leverage inside any technological relationship. Without exit, consent becomes ceremonial. For BCI users, exit must be safe, supported and practical. It includes the ability to pause optional connectivity, export relevant personal settings, obtain a usable copy of records, transfer to qualified alternatives and discontinue the device with appropriate clinical support.
Interoperability is therefore a sovereignty issue, not just a technical preference. Where a user depends on a system, proprietary lock-in can turn one company’s business decision into a personal crisis. Standards that permit secure transfer, independent maintenance and continuity of essential functions reduce that risk.
Exit rights do not mean reckless self-modification. BCIs must be safely managed. But safety and freedom are not opposites. The goal is safe reversibility: a path to repair, transfer, pause or disconnect that protects the person rather than trapping them.
HSTP-1:2026: from principle to evidence
The Human-Sovereignty Protocol Standard, HSTP-1:2026, turns these commitments into a voluntary assessment framework for technologies that enter, alter, monitor or materially influence body, mind, identity, biological inheritance or consequential decisions. For a BCI, the assessment should examine real evidence: consent flows, access controls, data architecture, update governance, security testing, portability, failure planning, incident response and redress mechanisms.
The standard evaluates twenty requirements on a 0–5 scale, for a maximum score of 100. A score below 50 is rejected; 50–69 is transitional; 70–84 is conformant; 85–94 is advanced; and 95–100 is Sovereign by Design. But numbers do not erase principles. A Human-Sovereignty Red Line—such as compelled use, covert neural monitoring, unchallengeable remote control or no safe exit—cannot be offset by excellence elsewhere.
This is not a branding badge. It is a discipline of proof. A company should be able to show how its BCI protects a person when the product is working, when it is updated, when it fails and when the user decides to leave.
Innovation worthy of trust
BCI innovation should be ambitious. It should restore communication, reduce suffering and expand human possibility. But the future will not be improved by devices that create a new class of people whose agency depends on corporate servers, hidden data practices or permanent consent.
The Human-Sovereignty Test offers a better direction. Build BCIs that are secure without becoming opaque; useful without becoming coercive; connected without becoming extractive; and advanced without claiming authority over the people they serve. Let users understand, choose, refuse, challenge, repair, transfer and disconnect.
A BCI reaches true market readiness when it has earned the user’s trust through design, evidence and accountability. Technology may augment the mind. It must never own it. The final authority remains with the human being.